Target intelligence / Profile preview

Hydroxymethylglutaryl-CoA (HMG-CoA)

Target: HMG-CoA
Molecular classification: Metabolite, Coenzyme A derivative

Overview

Hydroxymethylglutaryl-CoA (HMG-CoA) is an intermediate in the mevalonate pathway, a crucial metabolic pathway responsible for the synthesis of cholesterol, isoprenoids, and other essential biomolecules. It is formed from acetyl-CoA and acetoacetyl-CoA through the action of HMG-CoA synthase. HMG-CoA itself is not a direct therapeutic target, but it is a precursor to mevalonic acid, the synthesis of which is regulated by HMG-CoA reductase, a well-established drug target for cholesterol lowering.

Other names: 3-hydroxy-3-methylglutaryl-CoAHMGCoA

Biological functions

Intermediate in mevalonate pathwayPrecursor to mevalonic acid

Disease associations

Indirectly related to hypercholesterolemiaIndirectly related to cardiovascular disease

Beyond the preview

Go deeper on Hydroxymethylglutaryl-CoA (HMG-CoA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hydroxymethylglutaryl-CoA (HMG-CoA).

Explore the full profile